Glucotrack announced progress on its fully implantable continuous blood glucose monitor development timeline. The company plans to file an FDA investigational device exemption in the fourth quarter of 2025. It remains on track to implant first patients in a long-term, multi-centre feasibility study in Australia in the third quarter. CEO Paul V. Goode said the IDE filing would enable a multicentre US pilot study launch in 2026. The CBGM system is designed for three years of continuous, real-time blood glucose monitoring without on-body external components. Unlike traditional CGMs, the device measures glucose directly from the blood to eliminate interstitial fluid lag times. Glucotrack reported positive first-in-human results from a Brazilian study presented at the American Diabetes Association meeting. The data validated the system’s safety and performance profile. Goode said the company has strengthened its capital structure by removing warrant liability and reducing share dilution risks. The device aims to offer a less intrusive and more convenient monitoring option for diabetes patients. Glucotrack is positioning its CBGM as a differentiated, long-term solution for millions living with diabetes.